DAEWOONG PHARMACEUTICAL CO.LTD.
Daewoong
Global Healthcare Group
The Best Partner for You
Global Healthcare Group
The Best Partner for You
Achievements
We are conducting Open Collaboration actively to improve our research capacities
Platform Technology
Present ~ 2016
- 2024
- Fexuclue’s cumulative sales surpassed KRW 100 billion (24.May)
- Phase 3 trials of Atopic Dermatitis for Dogs treatment ‘DWP212525’ approved
- Phase 3-3(VELOS-4) trials begin for dry eye syndrome treatment ‘HL036’ in the United States
- 2023
- License-out of a first-in-class PRS inhibitor Bersiporocin in the Greater China region
- Codevelopment of anti-cancer treatment
- Exclusive licensing agreement for development and commercialization of Anti-Cancer Drug Generic DWJ108U in the U.S
- 2022
- Phase 3 topline results announced for enavogliflozin, both for monotherapy and combination therapy with metformin
- Investigational new drug (IND) Phase 2 study approved for ‘DWP708’ EGF cream
- Joint research MOU with Pin Therapeutics for new drugs using protein lysis technology
- Successful completion of Phase 3 trials for three-drug combination therapy of enavogliflozin, a new diabetes treatment
- Fexuclue receives a Korea New Drug Development Award: A Grand Prize in the area of new drug development
- Phase 3 trials for enavogliflozin approved in China
- Concluded an MOU with the Seoul National University Hospital for the establishment of infrastructure for restorative medicine and clinical research on advanced biologics
- New drug development agreement signed with KB Biomed to develop a modified treatment for osteoporosis using the technology for the oral administration of protein
- Application for marketing approval of Fexuclue Tabelt, a new treatment for GERD, filed in the Philippines, Indonesia, Thailand and four countries in Central and South America
- Approval of domestic new diabetes drug No. 36 Envlo
- Phase 3 clinical trial of Nabota for chin reduction successfully carried out for the first time in the world
- MOU for cooperation signed with DCGen for breast cancer symptom prediction kit
- Marketing approval obtained in Saudi Arabia and Ukraine for Nabota
- Declared the vision of ‘Global No.1 in Pharmaceutical Preparations by 2030’: Increased concentration on promising preparation technologies and open collaboration
- Multinational Phase 2 trials begin for DWN12088, a new treatment for idiopathic pulmonary fibrosis
- MOU signed with Cutis Bio for the development of environment-friendly, sustainable drug substances and their commercialization
- Joint development agreement signed with Sky Therapeutics for development of percutaneously absorbed treatments based on solubilization technology
- Stem cell CDMO agreement signed with Research Institute of Hearing Enhancement of Yonsei University and Affyxell therapeutics
- Fexuclue Tablet, a new GERD treatment, is released
- Daewoong Rosuvastatin Tablet 2.5mg Low-Volume obtains marketing approval
- DWN12088 becomes the first new drug for idiopathic pulmonary fibrosis to be designated by FDA for the fast-track approval process
- Obtained permit from the Ministry of Food and Drug Safety for an advanced cell product treatment facility and for regenerative medicine
- Selected as an R&D project (development of cell treatment products) by the Korean Fund for Regenerative Medicine
- Phase 1 trials completed for IVL3001, a continuously sustained long-term injection product for the treatment of alopecia areata, in Australia
- Phase 1 trials in the United States for the new drug for autoimmune disease treatment approved by FDA
- ‘Fexuclue’ acquires gastritis as an additional indication after a month of its release
- Phase 2 trials of botulinum toxin for cervical dystonia successfully completed in the United States
- Nabota launched in Europe (product name in the UK is Nuceiva)
- High-volume dexamethasone for oral administration approved in Korea for the first time, as “Dexa High Tablet"
- Crezet a low volume, a combination drug (containing rosuvastatin) for hyperlipidemia, is released, expanding the lineup of treatment products for abnormal lipidemia
- Fexuclue obtains marketing approval from the Food and Drug Administration of the Philippines
- Approval of Vemliver Tab.
- Selected as an R&D project by the Korea Drug Development Fund (Phase 2 clinical trials of DWN12088 for idiopathic pulmonary fibrosis)
- 2021
- Received government funding for manufacturing equipment of COVID-19 treatment drug candidate DWRX2003
- Contracts signed for the entry of Fexuprazan, a treatment for gastroesophageal reflux disease (GERD), in US, China and 6 Middle East markets
- Obtained approval for advanced biologics manufacturing
- V-Olet, an injection to reduce excessive jaw fat has been released
- Joint R&D with OncoCross to discover new indications for enavogliflozin and DWN12088
- Announcement of Phase 1 clinical trial results of DWN12088 in Australia, the first PRS-inhibiting pulmonary fibrosis treatment in the world
- Pulmonary fibrosis treatment ‘DWN12088’ received additional designation from US FDA as a rare drug
- Contract signed with D&D Pharmatek to develop orally administered peptide and protein preparations
- Phase 3 topline results of botulinum toxin product Nabota announced in China
- IVL3001, a continuously sustained long-term injection product for the treatment of alopecia areata, enters Phase 1 clinical trials in Australia
- Fexuclue tablet, a new treatment for GERD, obtained marketing approval in Korea
- Application filed in China for sales approval of Nabota
- 2020
- Developed COVID-19 treatment and selected for a government-sponsored project
- Daewoong Pharmaceutical’s Olostar was listed in the 2020 National R&D Excellence Top 100.
- Novel diabetes drug Enavogliflozin designated for expedited review for the first time in Korea and conducted a phase 3 clinical trial
- Registered as a bio-pharmaceutical accelerator, and sign an MOU with Gyeongsangnam-do, Gimhae, and Inje University
- Established iN Therapeutics, a drug discovery company (spun off from Daewoong Pharmaceutical)
- Selected as a company to be supported by the Ministry of Food and Drug Safety (MDFS) for Quality by Design (QbD)
- Independently developed botulinum toxin Nabota obtained marketing authorization in Taiwan and Brazil
- Obtained halal certification for Easyef Topical Solution and Epodion through Daewoong Infion, a joint venture in Indonesia
- Concluded agreements with Mexico and Brazil to export the next-gen gastroesophageal reflux disease drug Fexuprazan
- Established AffyXell Therapeutics, a joint venture specializing in cellular therapeutics, with the British biotech company Avacta
- 2019
- Acquired the international standard ISO 9001 certification for a quality management system (QMS)
- Received the Minister’s Award (Ministry of Science and ICT) as an institute of outstanding research note management
- Completed phase-3 clinical trial on Fexuprazan, a next-generation drug for gastroesophageal reflux
- Awarded by the government as an outstanding innovative pharmaceutical company
- DWN12088, a new drug for pulmonary fibrosis, designated as an orphan drug by the USFDA
- Urusa 300mg obtained indication for prevention of postgastrectomy cholelithiasis, being the first in the world
- Officially launched Jeuveau, an internally developed botulinum toxin, in the US
- Launched Olomax, a compound of three agents (olmesarta, rosuvastatin and amlopidine)
- Phase-3 clinical trial result of Nabota in the US published in an SCI-grade international journal
- DWN12088, a new drug for pulmonary fibrosis, selected for the inter-governmental support project
- Internally developed botulinum toxin approved by USFDA, being the first in Asia
- 2018
- Nabota obtained indication for eye wrinkles as the first botulinum toxin in Korea
- DWP14012, a new drug for gastroesophageal reflux, selected for inter-governmental support project
- 2016
- Completed construction of the Daewoong Bio Center
- Meropenem Inj, an antibiotic, approved by the USFDA
2015 ~ 2011
- 2015
- Olostar won the Technology Award for new drug development at the 16th Korea New Drug Award (KNDA)
- Began joint development in the field of antibody through M&A with HanAll BioPharma
- 2014
- Received a Prime Minister Citation in the science and technology category of the Korea New Growth Management Awards
- Won the Technology Award for new drug development at the 15th Korea New Drug Award (KNDA)
- Nabota selected as a World Class Product of Korea by the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Trade-Investment Promotion Agency (KOTRA)
- Released Nabota, a botulinum toxin, in Korea
- Released Olostar, a new drug compound of olmesartan and rosuvastatin
- 2013
- Won the 2013 Innovative Pharmaceutical Company Award
- 2012
- Caretropin Pen won the 2011-2012 World Star Award
- Selected for World Class 300, a global business development project
- Selected as an Innovative Pharmaceutical Company
- 2011
- Caretropin Inj. received the Minister’s Award
(Ministry of Knowledge Economy)
2010 ~ 2001
- 2008
- Easyef acquired the International Nonproprietary Name (INN) certified by the World Health Organization (WHO) as the first in the world
- 2005
- CoenzymeQ10 won the Minister’s Award (Ministry of Health and Welfare) at the Outstanding Technology Contest of the Health Industry Technologies Exposition Korea
- CoenzymeQ10 won the Jang Yong-shil Award
- Released Luphere, an anticancer agent
- 2003
- Succeeded in developing CoenzymeQ10, being the second in the world
- Easyef Topical Solution won second prize at the Korea New Drug Award
(Korea Drug Research Association: KNDA)
- 2002
- Easyef Topical Solution awarded as one of 100 Outstanding Patented Products
- 2001
- Released Easyef Topical Solution, Korea’s first new bio-pharmaceutical drug
- Acquired the KT (Korea Good Technology) mark for Easyef
2000 ~ Founded
- 1997
- Won Outstanding Achievement Award (Korean Intellectual Property Office) for the patented technology of Easyef
- 1987
- Received the Iron Tower Order of Industrial Service Merit in the science and technology category on the 1st Science Day
- Acquired the first genetic engineering patent in Korea
- 1983
- Established Daewoong Central R&D Institute
- 1974
- Established Subsidiary Pharmaceutical Research Center